Cyclophilin inhibitors in hepatitis C viral infection

Expert Opinion on Investigational Drugs

Volumn 16, Issue 9, 2007, Pages 1345-1354

  Flisiak, Robert ^a   Dumont, Jean Maurice ^b   Crabbé, Raf ^b  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b DEBIOPHARM SA   (Switzerland)

Author keywords

Anti HCV treatment; Cyclophilin; Cyclophilin inhibitor; Debio 025; Hepatitis C; NIM 811

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; BETA INTERFERON; BIL 2061; CONSENSUS INTERFERON; CYCLOPHILIN; CYCLOPHILIN INHIBITOR; CYCLOSPORIN A; CYCLOSPORIN DERIVATIVE; DEBIO 025; INTERFERON; ISOMERASE; NIM 811; PEGINTERFERON; PEGINTERFERON ALPHA; PLACEBO; PREDNISONE; PROTEIN INHIBITOR; PROTEINASE INHIBITOR; RIBAVIRIN; RNA POLYMERASE; SCH 503034; SCY 635; TACROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALOPICITABINE; VIRUS RNA; VX 950; ENZYME INHIBITOR;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; DRUG WITHDRAWAL; ENZYME ACTIVITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IN VITRO STUDY; ISOMERIZATION; MONOTHERAPY; NONHUMAN; PROTEIN FOLDING; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; VIRUS CELL INTERACTION; VIRUS REPLICATION; VIRUS RESISTANCE; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; METABOLISM;

ANIMALS; ANTIVIRAL AGENTS; CYCLOPHILINS; ENZYME INHIBITORS; HEPACIVIRUS; HEPATITIS C; HUMANS;

EID: 34548567684     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.9.1345     Document Type: Review

References (62)

1. Hepatitis C - global prevalence (update). Wkly Epidemiol. Rec. (2000) 75(3):18-19.
2. ALTER HJ: HCV natural history: the retrospective and prospective in perspective. J. Hepatol. (2005) 43(4):550-552.
3. ZOULIM F, CHEVALLIER M, MAYNARD M, TREPO C: Clinical consequences of hepatitis C virus infection. Rev. Med. Virol. (2003) 13(1):57-68.
4. HUGHES CA, SHAFRAN SD: Chronic hepatitis C virus management: 2000 - 2005 update. Ann. Pharmacother. (2006) 40(1):74-82.
5. FRIED MW, SHIFFMAN ML, REDDY KR et al.: Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. (2002) 347(13):975-982.
6. MANNS MP, MCHUTCHISON JG, GORDON SC et al.: Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 358(9286):958-965.
7. LINDENBACH BD, RICE CM: Unravelling hepatitis C virus replication from genome to function. Nature (2005) 436(7053):933-938.
8. PENIN F, DUBUISSON J, REY FA, MORADPOUR D, PAWLOTSKY JM: Structural biology of hepatitis C virus. Hepatology (2004) 39(1):5-19.
9. REESINK HW, ZEUZEM S, WEEGINK CJ et al.: Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a Phase Ib, placebo-controlled, randomized study. Gastroenterology (2006) 131(4):997-1002.
10. KIEFER T, SARRAZIN C, MILLER J et al.: Combination of telaprevir (VX-950) and PEG-IFN-α suppressed both wild-type virus and resistance variants in HCV genotype 1-infected patients in a 14-day Phase IB study. Hepatology (2006) 44:A222 (Abstract 92).
11. ZEUZEM S, SARRAZIN C, WAGNER F: Combination therapy with the HCV protease inhibitor, SCH 503034, plus peg-intron in hepatitis C genotype 1 peg-intron non-responders: Phase Ib results. Hepatology (2005) 42:A276 (Abstract 201).
12. O'BRIEN C, GODOFSKY E, RODRIQUEZ-TORRES M: Randomized trial of valopicitabine (NM283) alone or with peg-interferon vs retreatment with peg-interferon plus ribavirin in hepatitis C patients with previous non-response PEGIFN/RBV: first interim results. Hepatology (2005) 42:A234 (Abstract 95).
13. LAWITZ E, NGUYEN T, YOUNES Z et al.: Valopicitabine (NM283) plus PEG-interferon in treatment-naive hepatitis C patients with HCV genotype-1 infection: HCV RNA clearance during 24 weeks of treatment. Hepatalogy (2006) 44:A223 (Abstract 93).
14. VILLANO S, HOWE A, RAIBLE D et al.: Analysis of HCV NS5B genetic variants following monotherapy with HCV-796, a non-nucleoside polymerase inhibitor, in treatment-naive HCV-infected patients. Hepatology (2006) 44:A607 (Abstract 1127).
15. ROBERTS S, COOKSLEY G, DORE G et al.: Results of a Phase IB multiple dose study of R1626 a novel nucleoside analog targetting HCV polymerase in chronic HCV genotype 1 patients. Hepatology (2006) 44:A692 (Abstract LB2).
16. KOLETSKY AJ, HARDING MW, HANDSCHUMACHER RE: Cyclophilin: distribution and variant properties in normal and neoplastic tissues. J. Immunol. (1986) 137(3):1054-1059.
17. EDLICH F, FISCHER G: Pharmacological targeting of catalyzed protein folding: the example of peptide bond cis/trans isomerases. Handb. Exp. Pharmacol. (2006) (172):359-404.
18. RYFFEL B, WOERLY G, GREINER B et al.: Distribution of the cyclosporine binding protein cyclophilin in human tissues. Immunology (1991) 72(3):399-404.
19. NAKAGAWA M, SAKAMOTO N, TANABE Y et al.: Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology (2005) 129(3):1031-1041.
20. WATASHI K, ISHII N, HIJIKATA M et al.: Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol. Cell (2005) 19(1):111-122.
21. WATASHI K, HIJIKATA M, HOSAKA M, YAMAJI M, SHIMOTOHNO K: Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology (2003) 38(5):1282-1288.
22. FIRPI RJ, ZHU H, MORELLI G et al.: Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transplant. (2006) 12(1):51-57.
23. INOUE K, SEKIYAMA K, YAMADA M et al.: Combined interferon α2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial. J. Gastroenterol. (2003) 38(6):567-572.
24. MA S, BOERNER JE, TIONGYIP C et al.: NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with α interferon. Antimicrob. Agents. Chemother. (2006) 50(9):2976-2982.
25. PAESHUYSE J, KAUL A, DE CLERCQ E et al.: The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology (2006) 43(4):761-770.
26. FLISIAK R, HORBAN A, KIERKUS J et al.: The cyclophilin inhibitor DEBIO-025 has a potent dual anti-HIV and anti-HCV activity in treatment-naive HIV/HCV co-infected subjects. 57th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, USA (27-31 October 2006).
27. GOTHEL SF, MARAHIEL MA: Peptidyl-prolyl cis-trans isomerases, a superfamily of ubiquitous folding catalysts. Cell Mol. Life Sci. (1999) 55(3):423-436.
28. STEPKOWSKI SM: Molecular targets for existing and novel immunosuppressive drugs. Expert Rev. Mol. Med. (2000) 2000:1-23.
29. CASTRO AP, CARVALHO TM, MOUSSATCHE N, DAMASO CR: Redistribution of cyclophilin A to viral factories during vaccinia virus infection and its incorporation into mature particles. J. Virol. (2003) 77(16):9052-9068.
30. FRANKE EK, YUAN HE, LUBAN J: Specific incorporation of cyclophilin A into HIV-1 virions. Nature (1994) 372(6504):359-362.
31. LUBAN J: Cyclophilin A, TRIM5, and resistance to human immunodeficiency virus type 1 infection. J. Virol. (2007) 81(3):1054-1061.
32. TOWERS GJ, HATZIIOANNOU T, COWAN S et al.: Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nat. Med. (2003) 9(9):1138-1143.
33. YURCHENKO V, CONSTANT S, BUKRINSKY M: Dealing with the family: CD147 interactions with cyclophilins. Immunology (2006) 117(3):301-309.
34. YAO Q, LI M, YANG H et al.: Roles of cyclophilins in cancers and other organ systems. World J. Surg. (2005) 29(3):276-280.
35. ALLAIN F, DURIEUX S, DENYS A, CARPENTIER M, SPIK G: Cyclophilin B binding to platelets supports calcium-dependent adhesion to collagen. Blood (1999) 94(3):976-983.
36. ALLAIN F, BOUTILLON C, MARILLER C, SPIK G: Selective assay for CyPA and CyPB in human blood using highly specific anti-peptide antibodies. J. Immunol. Methods (1995) 178(1):113-120.
37. KONG W, LI S, LONGAKER MT, LORENZ HP: Cyclophilin C-associated protein is up-regulated during wound healing. J. Cell Physiol. (2007) 210(1):153-160.
38. WALDMEIER PC, ZIMMERMANN K, QIAN T, TINTELNOT-BLOMLEY M, LEMASTERS JJ: Cyclophilin D as a drug target. Curr. Med. Chem. (2003) 10(16):1485-1506.
39. RICE CM, YOU S: Treating hepatitis C: can you teach old dogs new tricks? Hepatology (2005) 42(6):1455-1458.
40. WATASHI K, SHIMOTOHNO K: Chemical genetics approach to hepatitis C virus replication: cyclophilin as a target for anti-hepatitis C virus strategy. Rev. Med. Virol. (2007) 17(4):245-52.
41. WATASHI K, SHIMOTOHNO K: Cyclophilin and viruses: cyclophilin as a cofactor for viral infection and possible anti-viral target. J. Drug Target Insights (2007) 1:9-18.
42. ISHII N, WATASHI K, HISHIKI T et al.: Diverse effects of cyclosporine on hepatitis C virus strain replication. J. Virol. (2006) 80(9):4510-4520.
43. MIYAMOTO M, KATO T, DATE T, MIZOKAMI M, WAKITA T: Comparison between subgenomic replicons of hepatitis C virus genotypes 2a (JFH-1) and 1b (Con1 NK5.1). Intervirology (2006) 49(1-2):37-43.
44. ROBIDA JM, NELSON HB, LIU Z, TANG H: Characterization of hepatitis C virus subgenomic replicon resistance to cyclosporine in vitro. J. Virol. (2007) 81(11):5829-5840.
45. TERAOKA S, MISHIRO S, EBIHARA K et al.: Effect of cyclosporine on proliferation of non-A, non-B hepatitis virus. Transplant. Proc. (1988) 20(3 Suppl. 3):868-876.
46. ROSENWIRTH B, BILLICH A, DATEMA R et al.: Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog. Antimicrob. Agents Chemother. (1994) 38(8):1763-1772.
47. GOTO K, WATASHI K, MURATA T et al.: Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811. Biochem. Biophys. Res. Commun. (2006) 343(3):879-884.
48. LIN K, BOERNER J, COOREMAN M: NIM811, a cyclophilin inhibitor targetting host-viral interaction, significantly enhances the antiviral activity of HCV polymerase inhibitors and reduces the emergence of resistance in vitro. First International Workshop on Hepatitis C Resistance and New Compounds, Boston, MA, USA (25-26 October 2006).
49. HANSSON MJ, MATTIASSON G, MANSSON R et al.: The nonimmunosuppressive cyclosporin analogs NIM811 and UNIL025 display nanomolar potencies on permeability transition in brain-derived mitochondria. J. Bioenerg. Biomembr. (2004) 36(4):407-413.
50. CHATTERJI U, BOBARDT MD, STANFIELD R et al.: Naturally occuring capsid substitutions render HIV-1 cyclophilin a independent in human cells and trim-cyclophilin resistant in owl monkey cells. J. Biol. Chem. (2005) 280(48):40293-40300.
51. PAESHUYSE J, COELMONT L, KAUL A et al.: The cyclophilin inhibitor Debio-025 is a potent inhibitor of hepatitis C virus replication in vitro. 57th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Boston, MA, USA (27-31 October 2006).
52. COELMONT L, PAESHUYSE J, KAPTEIN S et al.: The cyclophilin Debio-025, a potent inhibitor of hepatitis C virus replication in vitro has a unique resistance profile. 1st International Workshop on Hepatitis C Resistance and New Compounds. Boston, MA, USA (October 25-26 2006).
53. INOUE K, UMEHARA T, RUEGG UT et al.: Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo. Hepatology (2007) 45(4):921-928.
54. HOUCK D, HOPKINS S: Preclinical evaluation of SCY-635, a cyclophilin inhibitor with potent anti-HCV activity. Hepatology (2006) 44:A534 (Abstract 934).
55. NEYTS J: Selective inhibitors of hepatitis C virus replication. Antiviral. Res. (2006) 71(1-2):363-371.
56. COTLER SJ, MORRISSEY MJ, WILEY TE, LAYDEN TJ, JENSEN DM: A pilot study of the combination of cyclosporin A and interferon alfacon-1 for the treatment of hepatitis C in previous nonresponder patients. J. Clin. Gastroenterol. (2003) 36(4):352-355.
57. INOUE K, YOSHIBA M: Interferon combined with cyclosporine treatment as an effective countermeasure against hepatitis C virus recurrence in liver transplant patients with end-stage hepatitis C virus related disease. Transplant. Proc. (2005) 37(2):1233-1234.
58. BERENGUER M, AGUILERA V, PRIETO M et al.: Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients. Liver Transplant. (2006) 12(5):762-767.
59. HILGARD P, KAHRAMAN A, LEHMANN N et al.: Cyclosporine versus tacrolimus in patients with HCV infection after liver transplantation: effects on virus replication and recurrent hepatitis. World J. Gastroenterol. (2006) 12(5):697-702.
60. VILLAMIL F, LEVY G, GRAZI GL et al.: Long-term outcomes in liver transplant patients with hepatic C infection receiving tacrolimus or cyclosporine. Transplant. Proc. (2006) 38(9):2964-2967.
61. MCHUTCHISON JG, ZEUZEM S, BENHAMOU Y et al.: Interim antiviral and safety data with albumin interferon α-2B combined with ribavirin in a Phase IIB study conducted in a genotype 1, IFN-naive, chronic hepatitis C population. Hepatology (2006) 44:A614 (Abstract 1141).
62. JACOBSON I, POCKROS P, BENHAMOU Y et al.: Impact of taribavirin and ribavirin exposure on efficacy and anemia rates when combined with pegylated interferon α-2B in the treatment of chronic HCV. Hepatology (2006) 44:A610 (Abstract 1133).